Abstract
Background and Aims There is limited evidence on the link between ultra-processed food (UPF) intake and the risk of lung cancer (LC). This study examined the association between UPF and LC risk using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer trial.
Methods This study involved PLCO participants (n = 96,607, aged ≥ 55 years) who were followed between 1998 and 2009. Food items were categorized based on the NOVA classification. Cox regression models with inverse probability of censoring weighting (IPCW) were utilized to estimate the association between UPF intake and LC risk. The joint effect of UPF and diabetes was explored using additive hazard models to calculate the additional number of LC cases.
Results During a median follow-up period of 9.4 years, 1,596 incident LC cases were identified. UPF consumption (in %gram/day) showed no significant association with the overall risk of LC. However, adults with diabetes in the highest quintile of UPF intake had a significantly higher risk of LC (HR = 2.44; 95% CI: 1.27, 4.67) compared to participants without diabetes. A small excess risk due to the interaction between UPF and diabetes (0.13; 95% CI −0.32, 0.58) was observed, resulting in an additional 201 cases of LC per 105 person-years (95% CI: 70, 332) attributed to the highest UPF intake and diabetes interaction. Furthermore, a 10% increment in UPF intake (%kcal/day) increased the risk of LC by 32%.
Conclusions While UPF, in terms of weight contribution, is associated with a higher risk of LC in participants with diabetes, UPF (in %kcal/day), is associated with an increased risk of LC in all participants. Lowering UPF intake may help reduce the risk of LC in both diabetic patients and the general population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the trial was obtained from the US National Cancer Institute (NCI) Review Boards and written informed consent was obtained from each participant. The data for dietary history and lung cancer analysis were obtained using the Cancer Data Access System (CDAS) after obtaining approval from NCI (project registration: PLCO-982).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- BMI
- Body Mass Index
- BQ
- Baseline Questionnaire
- EPIC
- European Prospective Investigation into Cancer and Nutrition
- CVD
- Cardiovascular disease
- DHQ
- Dietary History Questionnaire
- FFQ
- Food Frequency Questionnaire
- LC
- Lung Cancer
- NCDs
- Non-communicable Diseases
- NCI
- National Cancer Institute
- PLCO
- Prostate, Lung, Colorectal and Ovarian Cancer
- UPF
- Ultra-processed Food
- UK
- United Kingdom.
